. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Anticancer Drugs. 2015 Sep;26(8):835–842. doi: 10.1097/CAD.0000000000000251

Table 1.

Median effects of nilotinib and MEK162 as single agents and in combination on head and neck squamous cell carcinoma cells in vitro.

Cell line	Single agent, IC50^*		Combination, IC50^*		Combination index simulations, Fa = 0.5	Interpretation

	Nilotinib, nmol/L	MEK162, nmol/L	Nilotinib, nmol/L	MEK162, nmol/L
UMSCC47	33.3	>200	1115	28.0	0.334 ± 96	Not conclusive
OSC19	7027	>200	472	11.8	0.089 ± 0.04	Synergistic
HN31	>8000	>200	710	17.7	0.085 ± 0.08	Synergistic
UMSCC17A	>8000	>200	802	20.0	0.011 ± 0.07	Synergistic

IC₅₀, half maximal inhibitory concentration.